Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

Related Posts

• Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis

  Background Checkpoint inhibitor pneumonitis (CIP) that does not respond to corticosteroids is termed steroid-refractory CIP.…

• Surufatinib and PD-1 Inhibitors Effective in Refractory mCRC

  KEY TAKEAWAYS The Phase II trial aimed to evaluate the efficacy of Surufatinib + PD-1…

• Correction: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity